Pfizer Corporation Hong Kong Limited 美國輝瑞科研製藥

UNDER

Indications¹

Treatment of hypertension. Treatment of clinical symptoms in benign prostatic hyperplasia (BPH) and for reduced urinary flow associated with BPH.

Clinical Evidence

IPSS , International Prostate Symptom Score; Qmax, maximum urine flow rate

Significant, rapid, clinically meaningful improvement in symptoms and urinary flow rate²

Safety Profile¹

CI:	Known hypersensitivity to quinazolines, doxazosin or any of the inert ingredients of Cardura XL.

SP:	Postural hypotension/syncope. Hepatic impairment. Pre-existing severe gastrointestinal narrowing. May impair ability to drive or operate machinery.

AR:	*Hypertension:* Palpitation, tachycardia. Vertigo. Abdominal pain, dry mouth, nausea. Asthenia, chest pain, peripheral oedema. Back pain, myalgia. Postural hypotension. Dizziness, headache. Bronchitis, coughing. Pruritus. Cystitis, urinary incontinence. *BPH:* Vertigo. Asthenia, peripheral oedema. Abdominal pain, dyspepsia, nausea. Influenza-like symptoms, respiratory tract infection, urinary tract infection. Back pain, myalgia. Dizziness, headache, somnolence. Bronchitis, dyspnea, rhinitis. Hypotension, postural hypotension.

DI:	Concomitant use with PDE-5 inhibitors may lead to symptomatic hypotension.

Dosages¹

Initially 4 mg once daily. Max: 8 mg once daily.

Strengths¹

4 mg, 8 mg.

Packing¹

GITS tab 4 mg x 30’s, 100’s. 8 mg x 100’s.

References

1. MIMS Annual Hong Kong. 2007/2008 edition.
2. Roehrborn CG, et al. Eur Urol 2005;48:445-452.

Please review the full product information or package insert before prescribing.